Ivermectin vs. Merck's New Antiviral, Molnupiravir
• mercola.com, Analysis by Dr. Joseph MercolaOne paper compared Merck's data on molnupiravir against peer-reviewed data on ivermectin and found ivermectin has a low side effect profile, costs less than molnupiravir and is more effective against SARS-CoV-2
